Bank of Montreal Can Sells 463,387 Shares of Insulet Corporation $PODD

Bank of Montreal Can lessened its position in shares of Insulet Corporation (NASDAQ:PODD) by 91.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,253 shares of the medical instruments supplier’s stock after selling 463,387 shares during the period. Bank of Montreal Can’s holdings in Insulet were worth $12,961,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in PODD. Crossmark Global Holdings Inc. lifted its holdings in Insulet by 3.4% during the 1st quarter. Crossmark Global Holdings Inc. now owns 3,036 shares of the medical instruments supplier’s stock worth $797,000 after purchasing an additional 100 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Insulet by 69.7% in the 1st quarter. Nisa Investment Advisors LLC now owns 7,445 shares of the medical instruments supplier’s stock valued at $1,955,000 after buying an additional 3,057 shares in the last quarter. Cerity Partners LLC increased its position in Insulet by 28.7% during the 1st quarter. Cerity Partners LLC now owns 10,232 shares of the medical instruments supplier’s stock worth $2,687,000 after buying an additional 2,284 shares during the period. Xponance Inc. lifted its holdings in shares of Insulet by 2.8% during the first quarter. Xponance Inc. now owns 16,007 shares of the medical instruments supplier’s stock worth $4,204,000 after buying an additional 441 shares in the last quarter. Finally, Diversify Wealth Management LLC lifted its holdings in shares of Insulet by 27.0% during the first quarter. Diversify Wealth Management LLC now owns 3,508 shares of the medical instruments supplier’s stock worth $881,000 after buying an additional 746 shares in the last quarter.

Insulet Trading Down 1.1%

Shares of PODD opened at $319.82 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50. The firm has a market cap of $22.51 billion, a price-to-earnings ratio of 97.21, a PEG ratio of 2.64 and a beta of 1.39. The business’s fifty day moving average is $325.06 and its 200-day moving average is $309.86.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same period last year, the firm posted $1.08 earnings per share. Insulet’s revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.39% of the company’s stock.

Analysts Set New Price Targets

PODD has been the subject of a number of recent research reports. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Royal Bank Of Canada lifted their price target on shares of Insulet from $365.00 to $370.00 and gave the company an “outperform” rating in a research report on Friday. Stifel Nicolaus assumed coverage on Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price target on the stock. Barclays raised their price objective on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $370.76.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.